On Jul. 9, 2020, BioSig Technologies and its subsidiary, ViralClear Pharma announced that it is partnering with Albany Molecular Research, a leading global contract research, development and manufacturing organization, for support in undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a standalone treatment or in combination with other anti-viral agents or immune modulators.